Results of a registry analysis on the real-world use of aflibercept 8 mg in treatment-naive and previously treated eyes with diabetic macular edema were presented at the American Society of Retina Specialists annual meeting.
“This is a registry study [on Eylea HD (aflibercept 8 mg, Regeneron)], so we don’t have individual patient-level data, and unfortunately, at this time, we don’t have the ability to look at the OCTs, but this, to me, is quite helpful in my day-to-day decision-making” Sunir J. Garg, MD, FACS, FASRS, chief of the retina service at Wills Eye Hospital and professor of